Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 46Prostate Adenocarcinoma 3Neoplasms 3Adenocarcinoma 2Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Prostatic Diseases 1PSA Level Greater Than Two 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Granulosa cell tumor of the ovary 1Genital Neoplasms, Male 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma 1

Interventions

Cisplatin 18Docetaxel 17Cetuximab 12Carboplatin 12Magnetic Resonance Spectroscopy 10pembrolizumab 9Radiotherapy 9Paclitaxel 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Biopsy 7Specimen Handling 6Radiotherapy, Intensity-Modulated 6Radiotherapy, Conformal 5Radiosurgery 5Fluorodeoxyglucose F18 5Chemotherapy, Adjuvant 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Nivolumab 4Bevacizumab 4sargramostim 3Radiation 3Platinum 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Salivary Gland Neoplasms × luprolide acetate gel depot × Clear all
NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡